Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target Price
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 11/20/13 -- announced today that it has initiated coverage on (OTCQB: TRGM) ("The Company," or "TRGM"); with a twelve month target price of $2.75. Ross Silver, Principal Analyst at Vista Partners, stated, "TRGM develops and sells a line of patented prescription medical food products that are currently sold in the United States through a network of distributors and directly to physicians who dispense medical foods and other pharmaceutical products through their office practices. With recent reductions in physician reimbursements for medical services by Medicare, workers compensation and private insurance companies, many physicians are actively seeking additional sources of practice revenues." Mr. Silver concludes, ", a subsidiary of , has been actively acquiring medical food companies, one of which was Prometheus Laboratories, a firm specializing in diagnostics and pharmaceuticals in gastrointestinal and oncology. According to an article by , may have paid 500M Swiss Francs ($550M U.S.) to 1B Swiss Francs ($1.1B U.S.) for Prometheus."
To download a FREE copy of the research report, please visit and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing in and providing investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.11.2013 - 14:00 Uhr
Sprache: Deutsch
News-ID 318662
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Initiates Coverage on Targeted Medical Pharma, Inc. (Ticker: TRGM); $2.75 Target Price"
steht unter der journalistisch-redaktionellen Verantwortung von
Targeted Medical Pharma, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
